Hyperparathyroidism is a condition where the parathyroid glands produce too much parathyroid hormone, causing high calcium levels in the blood. It can lead to symptoms like bone pain, fatigue, and kidney stones. Treatment includes surgery or medications, depending on the underlying cause and severity.
<h2 dir="ltr">Epidemiology Segmentation</h2>
<ul>
<li dir="ltr" aria-level="1">
Total Prevalent Cases of Hyperparathyroidism
</li>
<li dir="ltr" aria-level="1">
Total Diagnosed Prevalence Cases of Hyperparathyroidism
</li>
<li dir="ltr" aria-level="1">
Type-Specific Cases of Hyperparathyroidism
</li>
<li dir="ltr" aria-level="1">
Age-Specific Cases of Hyperparathyroidism
</li>
<li dir="ltr" aria-level="1">
Gender-specific Cases of Hyperparathyroidism
</li>
<li dir="ltr" aria-level="1">
&middot; Total Treated cases of Hyperparathyroidism
</li>
</ul>
<h3 dir="ltr"><a href="https://www.delveinsight.com/report-store/hypoparathyroidism-epidemiology-forecast">Hyperparathyroidism Epidemiology</a></h3>
<ul>
<li dir="ltr" aria-level="1">
In 2024, the total diagnosed prevalent cases of hyperparathyroidism in the 7MM were approximately 5.4 million, with around 2.61 million cases in the U.S., mostly among individuals aged 60 and above.
</li>
<li dir="ltr" aria-level="1">
Females accounted for approximately 70% of hyperparathyroidism cases across the 7MM.
</li>
<li dir="ltr" aria-level="1">
Japan had about 479K diagnosed prevalent cases of hyperparathyroidism in 2024.
</li>
</ul>
<h3 dir="ltr"><a href="https://www.delveinsight.com/report-store/hyperparathyroidism-market">Hyperparathyroidism Market</a></h3>
<ul>
<li dir="ltr" aria-level="1">
In 2024, the U.S. dominated the hyperparathyroidism market in the 7MM, holding about 80% of the total market share.
</li>
<li dir="ltr" aria-level="1">
PARSABIV accounted for roughly 50% of the market share across the EU4 and the UK in 2024.
</li>
</ul>
<h3 dir="ltr">Hyperparathyroidism Market Drivers</h3>
<ul>
<li dir="ltr" aria-level="1">
Secondary hyperparathyroidism is a common complication of CKD, which is increasing globally, thereby driving demand for targeted therapies.
</li>
<li dir="ltr" aria-level="1">
Improved screening and diagnostic tools are enabling earlier diagnosis and treatment, boosting market growth.
</li>
</ul>
<h3 dir="ltr">Hyperparathyroidism Market Barriers</h3>
<ul>
<li dir="ltr" aria-level="1">
Many patients remain undiagnosed due to the nonspecific symptoms of hyperparathyroidism, delaying treatment initiation and impacting market penetration.
</li>
<li dir="ltr" aria-level="1">
The expense of long-term therapies and surgical interventions, coupled with inconsistent insurance coverage, can restrict patient access in several regions.
</li>
</ul>
<h3 dir="ltr"><a href="https://www.delveinsight.com/report-store/hyperparathyroidism-pipeline-insight">Hyperparathyroidism Key Players</a></h3>
<ul>
<li dir="ltr" aria-level="1">
Vidasym Inc.
</li>
<li dir="ltr" aria-level="1">
Mitsubishi Tanabe Pharma
</li>
<li dir="ltr" aria-level="1">
Shanghai Hengrui Pharmaceutical
</li>
</ul>
And others.

Hyperparathyroidism Market Infographic

Hyperparathyroidism Market

Hyperparathyroidism Symptoms, Treatment, epidemiology, companies, drugs, infographic is a short guide to understand the problem and market landscape